Search - tctmd.com

Displaying 301 - 320 of 344

Sort: Relevancy | Date

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Stefanie Schüpke

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

News Daily News

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Todd Neale

August 20, 2014

News Industry News

First patient enrollment in MASCOT registry represents major milestone for COMBO™ Dual Therapy Stent and OrbusNeich’s clinical program

July 16, 2014

News Industry News

OrbusNeich Announces First Patient Enrollment in Physician-Initiated Study to Evaluate the Potential for Shorter-Term Dual Antiplatelet Therapy in ACS Patients

June 19, 2014

News Daily News

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Yael L. Maxwell

May 01, 2014

Presentation

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Presenter: Sripal Bangalore

April 22, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

March 24, 2014

News Daily News

Transradial Approach May Balance Bleeding Benefits of Bivalirudin in Primary PCI

Jason Kahn

January 15, 2014

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Industry News

First Patients Enrolled in REMEDEE Registry to Evaluate Long-Term Safety and Performance of OrbusNeich’s COMBO Dual Therapy Stent™ in Routine Practice

August 06, 2013

News Industry News

OrbusNeich Launches World’s First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents

May 27, 2013

News Daily News

Prasugrel Noninferior to Ticagrelor in STEMI, but Both Require Hours to Achieve Effect

Yael L. Maxwell

May 13, 2013

News Industry News

OrbusNeich’s COMBO Dual Therapy Stent™ to Be Featured in Symposium at the 79th Annual Meeting of the German Cardiac Society in Mannheim

April 01, 2013

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Daily News

Dabigatran Usage up, Both for A-fib and Off-Label Indications

September 12, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

Advertisement

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

First patient enrollment in MASCOT registry represents major milestone for COMBO™ Dual Therapy Stent and OrbusNeich’s clinical program

OrbusNeich Announces First Patient Enrollment in Physician-Initiated Study to Evaluate the Potential for Shorter-Term Dual Antiplatelet Therapy in ACS Patients

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

Transradial Approach May Balance Bleeding Benefits of Bivalirudin in Primary PCI

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

First Patients Enrolled in REMEDEE Registry to Evaluate Long-Term Safety and Performance of OrbusNeich’s COMBO Dual Therapy Stent™ in Routine Practice

OrbusNeich Launches World’s First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents

Prasugrel Noninferior to Ticagrelor in STEMI, but Both Require Hours to Achieve Effect

OrbusNeich’s COMBO Dual Therapy Stent™ to Be Featured in Symposium at the 79th Annual Meeting of the German Cardiac Society in Mannheim

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Dabigatran Usage up, Both for A-fib and Off-Label Indications

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content